MIESF yields 0.57% · PFE yields 6.13%● Live data
📍 MIESF pulled ahead of the other in Year 1
Combined, MIESF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MIESF + PFE for your $10,000?
Mitsui E&S Holdings Co., Ltd. engages in the shipbuilding and engineering businesses worldwide. The company operates through four segments: Ship, Ocean Development, Machinery, and Engineering. The Ship segment builds commercial ships, naval ships, high speed passenger/vehicle ferries, offshore structures, underwater TV vehicles, steel structures, and ship related equipment; and provides design engineering services. The Ocean Development segment provides floating production storage offloading vessels. The Machinery segment offers marine and stationary diesel engines, marine equipment, gas engines, steam turbines, blowers, process compressors and equipment, gas turbines, cogeneration systems, container cranes, industrial cranes, container terminal management systems, HWM manipulators, wave generators, and induction heaters, as well as equipment of radar sensing for underground and construction. The Engineering segment engages in the power generation and overseas civil/architectural works. The company also engages in the telecommunication equipment related, systems development, gas carriers engineering, and social infrastructure related businesses, as well as operates special facilities for naval ships and aircraft related business. The company was formerly known as Mitsui Engineering & Shipbuilding Co., Ltd. Mitsui E&S Holdings Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Full MIESF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.